Immuneering annual gross margin
2020
2021
2022
Immuneering's gross margin was 50.11% for fiscal 2022.
View full Immuneering company overview| Fiscal year | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| 2022 | 2022-12-31 | 50.11% | +5.55 pp |
| 2021 | 2021-12-31 | 44.56% | −0.05 pp |
| 2020 | 2020-12-31 | 44.61% | — |
| Fiscal quarter | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| Q4 2022 | 2022-12-31 | 100.00% | +108.77 pp |
| Q3 2022 | 2022-09-30 | 49.60% | −4.96 pp |
| Q2 2022 | 2022-06-30 | 49.23% | −2.50 pp |
| Q1 2022 | 2022-03-31 | 50.55% | +5.23 pp |
| Q4 2021 | 2021-12-31 | −8.77% | −62.62 pp |
| Q3 2021 | 2021-09-30 | 54.56% | +3.86 pp |
| Q2 2021 | 2021-06-30 | 51.73% | — |
| Q1 2021 | 2021-03-31 | 45.31% | — |
| Q3 2020 | 2020-09-30 | 53.85% | — |
| Q2 2020 | 2020-06-30 | 50.70% | — |
Across the available reported history, Immuneering's gross margin increased from 44.56% to 50.11%, a change of +5.55 percentage points. The latest reported quarter, Q4 2022, shows 100.00%.
Gross margin measures the percentage of revenue remaining after the direct costs of producing goods or services. It helps show how efficiently a company turns sales into gross profit before operating expenses.
TickerStat calculates gross margin as SEC-reported gross profit divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Immuneering filings at SEC.gov ↗